OTCMKTS:AFFY - Affymax Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0170 0.00 (0.00 %)
(As of 06/18/2018 06:00 AM ET)
Previous Close$0.0170
Today's Range$0.0170 - $0.0170
52-Week Range$0.0110 - $0.0590
Volume11,057 shs
Average Volume11,769 shs
Market Capitalization$640,000.00
P/E RatioN/A
Dividend YieldN/A
Beta2.09

About Affymax (OTCMKTS:AFFY)

Affymax logoAffymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Receive AFFY News and Ratings via Email

Sign-up to receive the latest news and ratings for AFFY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:AFFY
CUSIP00826A10
Phone650-812-8700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares37,490,000

Affymax (OTCMKTS:AFFY) Frequently Asked Questions

What is Affymax's stock symbol?

Affymax trades on the OTCMKTS under the ticker symbol "AFFY."

Who are some of Affymax's key competitors?

Who are Affymax's key executives?

Affymax's management team includes the folowing people:
  • Mr. Mark G. Thompson, Chief Financial Officer and Sec. (Age 56)
  • Mr. Jonathan M. Couchman CFA, Chief Exec. Officer, Pres and Director (Age 48)
  • Dr. Tracy J. Dunn Ph.D., J.D., VP of Intellectual Property & Legal Affairs (Age 55)
  • Ms. Kay Slocum, Sr. VP of HR (Age 71)

Has Affymax been receiving favorable news coverage?

News headlines about AFFY stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Affymax earned a news sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Affymax?

Shares of AFFY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affymax's stock price today?

One share of AFFY stock can currently be purchased for approximately $0.0170.

How big of a company is Affymax?

Affymax has a market capitalization of $640,000.00.

How can I contact Affymax?

Affymax's mailing address is 19200 STEVENS CREEK BOULEVARD SUITE 240, CUPERTINO CA, 95014. The biopharmaceutical company can be reached via phone at 650-812-8700 or via email at [email protected]


MarketBeat Community Rating for Affymax (AFFY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Affymax and other stocks. Vote "Outperform" if you believe AFFY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFFY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.